Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
BMC Cancer|March 5, 2022
The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participantsQing Wu, Shuimei Luo, Xianhe XieJournal of Immunotherapy (Hagerstown, Md. : 1997)|June 8, 2022
Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?Qing Wu, Shuimei Luo, Xianhe XieDisease Markers|January 2, 2023
Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint InhibitorsLuying Wan, Chunlan Wu, Shuimei Luo, et al.Oncotarget|June 10, 2015
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastasesShuimei Luo, Long Chen, Xiuping Chen, et al.Cancer Medicine|June 30, 2022
Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patientsLuying Wan, Chunlan Wu, Qin Wu, et al.Life Sciences|August 15, 2025
Upregulation of PRSS27 driven by super-enhancers attenuates oxidative stress and apoptosis via activating PI3K/AKT pathway in lung adenocarcinomaZiming Wang, Haofeng Yin, Qing Wu, et al.Epigenetics|February 3, 2023
Upregulation of KHDC1L promotes the proliferation and inhibits apoptosis in head and neck squamous cell carcinomaQi Zhang, Shuimei Luo, Yang Luo, et al.Journal of Immunology Research|November 21, 2022
Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast CancerLili Wang, Shuimei Luo, Ziming Wang, et al.Cancer Letters|March 15, 2024
Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinomaShuimei Luo, Yang Luo, Ziming Wang, et al.Oncotarget|December 1, 2016
Efficacy and safety of angiogenesis inhibitors in small-cell lung cancerHeng Lin, Lina Li, Shuimei Luo, et al.Pageof 2